Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Omega-3 wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Probably helps
2 of 3 studies with measurable effects showed benefit.
Top outcomes
Verdict
Probably helps
18 of 27 studies with measurable effects showed benefit.
Top outcomes
500mg twice daily
Morning and evening with meals
Niacinamide tablets (500mg)
2-3g combined EPA+DHA daily
With meals containing fat
Triglyceride form fish oil
3-12 months
8 weeks
Days
First days
4-8 weeks
2-4 weeks
Immediate
4-12 weeks
A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention.
The New England journal of medicine (2015) · Rct · n=386
ONTRAC: phase-3, double-blind RCT randomizing 386 patients with ≥2 prior non-melanoma skin cancers to 500 mg nicotinamide twice daily or placebo for 12 months
Skin Cancer Prevention and Antiaging: Role of Nicotinamide.
International journal of molecular sciences (2026) · Review
Review of the biological rationale and clinical evidence for nicotinamide and NAD+ precursors in photoaging and cutaneous carcinogenesis
Topical nicotinamide compared with clindamycin gel in the treatment of inflammatory acne vulgaris.
International journal of dermatology (1995) · Rct · n=76
Double-blind RCT of 76 patients randomized to 4% nicotinamide gel or 1% clindamycin gel twice daily for 8 weeks for moderate inflammatory acne
Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer
The New England journal of medicine (2019) · Rct · n=25871
During a median follow-up of 5.3 years, a major cardiovascular event occurred in 386 participants in the n-3 group and in 419 in the placebo group (hazard ratio, 0.92; 95% confidence interval [CI], 0.80 to 1.06; P=0.24).
Omega-3 fatty acids for intermittent claudication
The Cochrane database of systematic reviews (2024) · Meta analysis · n=1830
Omega-3 compared with a control may have little to no effect on ankle-brachial index (MD -0.02, 95% CI -0.08 to 0.04; 3 studies, 168 participants; very low-certainty evidence).
A systematic review and meta-analysis of the omega-3 fatty acids effects on brain-derived neurotrophic factor (BDNF)
Nutritional neuroscience (2024) · Meta analysis · n=587
The present systematic review and meta-analysis indicate the efficacy of omega-3 FAs in increasing the serum concentration of BDNF.
The ONTRAC RCT used 500 mg twice daily (1000 mg/day total) and reduced new non-melanoma skin cancers by 23%. Effect requires continuous use; it disappeared after discontinuation. Curve is indicative — only the 1000 mg/day regimen is directly RCT-supported.
Based on multiple meta-analyses showing EPA-dominant formulas >1g/day most effective. Effects plateau around 2-2.5g. Adjunctive use with antidepressants shows better outcomes than monotherapy.
AI-estimated from published studies. Interpret as directional guidance.
Omega-3 has a higher evidence score (9/10 vs 5.5/10) and wins in 2 of 3 categories.
For reduce inflammation, Omega-3 has a higher relevance score (90 vs 45).
No known interactions between Nicotinamide and Omega-3 have been documented in our database. However, always consult a healthcare provider before combining supplements.